Portage Biotech Inc <PRTG.O>: Losses of 6  cents announced for second quarter

Follow us on Google News:
 Portage Biotech Inc <PRTG.O>: Losses of 6  cents announced for second quarter
Image source: ©2022 Kalkine Media®

29 November 2022 10:05 p.m. ​All figures in US dollars. The loss announced by Portage Biotech Inc in the second quarter were higher than the Refinitiv mean estimate of losses. The company reported losses of -6 cents per share, 16 cents higher than the same quarter last year when the company reported EPS of -22 cents. Losses of -29 cents per share were anticipated by the three analysts providing estimates for the quarter. Wall Street expected results to range from -33 cents to -26 cents per share, with a forecasted mean of -29 cents per share. The company reported zero revenue, which is in line with the estimated revenue. RECOMMENDATIONS * The consensus recommendation for the company is "Buy". * The average consensus recommendation for the biotechnology & medical research peer group is also "Buy". FORECAST CHANGES * Three analysts are currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There was no change to the number of estimates. YEAR OVER YEAR * The company reported revenue of $0, a revenue figure is not available for the same quarter last year,​ * Previous quarterly performance (using earnings preferred measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Jun. 30 2022 -0.30​ -0.13 Beat Mar. 31 2022 -0.28 -0.56 Missed Dec. 31 2021 -0.27 -0.26 Beat​ Sep. 30 2021 -0.25 -0.22 Beat This summary was machine generated from Refinitiv data November 29 at 10:05 p.m.


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK